Company Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
The company was incorporated in 2015 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| IPO Date | May 24, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 297 |
| CEO | Sanj Patel |
Contact Details
Address: 23 Old Bond Street, Floor 3 London, WIS 4PZ United Kingdom | |
| Phone | 781 431 9100 |
| Website | kiniksa.com |
Stock Details
| Ticker Symbol | KNSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730430 |
| CUSIP Number | G5269C101 |
| ISIN Number | BMG5269C1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
| Eben Tessari | Senior Vice President and Chief Operating Officer |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Mark Ragosa C.F.A. | Senior Vice President and Chief Financial Officer |
| Michael R. Megna CPA | Chief Accounting Officer and Group Vice President of Finance |
| Mei Jang | Senior Vice President of Technical Operations |
| Chad Morin | Senior Vice President and Chief Compliance Officer |
| Madelyn Demsky Zeylikman | SVice President, General Counsel and Secretary |
| Carsten Boess M.B.A. | Executive Vice President of Corporate Affairs |
| Martina Struck Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 144 | Filing |
| Oct 29, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 144 | Filing |